Cohort study reveals anemia management strategies in chronic kidney disease, suggesting better options for treatment.
Anemia is a common complication of chronic kidney disease (CKD) and contributes to the progression of both CKD and heart failure. Although current guidelines recommend maintaining hemoglobin (Hb) within the target range, Hb levels often decline progressively under uremic conditions in advanced CKD. In Japan, five hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have been approved since 2021, expanding therapeutic options for anemia management. HIF-PHIs are expected to enhance iron utilization and may be effective in patients with hyporesponsiveness to erythropoiesis-stimulating agents (ESAs).
No takes yet. Share an insight, caveat, or question.
Miyauchi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: